SGR-1505

Phase 1Small molecule

SSchrödinger, Inc.

SGR-1505 is one of 4 small molecule programs targeting B-cell neoplasm. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

B-Cell NeoplasmRecruiting

B-Cell NeoplasmPhase 1

Recruiting

Competition

Competitive Landscape

3 competitors in B-Cell Neoplasm

#DrugCompanyPhaseTrials

Zamtocabtagene Autoleucel

MMiltenyi Biomedicine GmbH

Phase 2

1 2

Polivy

Zynlonta

SGR-1505

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

B-Cell Neoplasm

NCT05544019

Clinical

Trials by Indication[1]

B-cell neoplasm1 trial

Study of SGR-1505 in Mature B-Cell Neoplasms

Recruiting·SSchrödinger, Inc.·Phase 1·NCT05544019·98 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SGR-1505. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SGR-1505 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SGR-1505. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Schrödinger, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSchrödinger, Inc.

SGR-1505

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

B-cell neoplasm1 trial

References

Drug Info

Quick Facts

Related News